Ipsen
Manufacturing · France · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
70 Rue Balard, Paris, Île-de-France, 750...Phone Number
+33 158335000Website
www.ipsen.comRevenue
$4.4 BillionStock Symbol
IPNIndustry
About Ipsen
Ipsen Org Chart
Is Ipsen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Ipsen is spiking on competitors!
Earning: See what the market has to say on Ipsen recently announced quarterly report
Check if Ipsen has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Ipsen, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Ipsen
Product Launch: Get notified when Ipsen launches new products
Funding: Get notified immidiatlly once Ipsen has new funding data
Click to see if Ipsen had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Ipsen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ipsen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ipsen.
Ipsen Tech Stack
A closer look at the technologies used by Ipsen
Most Recent Scoops
Ipsen News & Media
IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026
Aggregated presentation by day and by marketIpsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis.IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026
Aggregated presentation by day and by marketIpsen S.A. (IPSEY) Q2 2026 Earnings Call Transcript
Ipsen S.A. (IPSEY) Q2 2026 Earnings Call July 30, 2026 8:00 AM EDTCompany ParticipantsDavid Loew - MD, CEO & DirectorAymeric Le Chatelier - Executive VP...
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ipsen
Founded in 1929 and headquartered in Boulogne, France, Ipsen Pharma is a global biopharmaceutical group focused on specialty care. The Group develops and commercializes medicines in therapeutic areas including oncology, neuroscience, and rare diseases.... Read More